Company Description
Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics.
Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data.
The company is also giving AI for robotics, smart factories, senior care, and women’s health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health.
The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.
Ainos, Inc. was incorporated in 1984 and is based in San Diego, California. Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation.
| Country | United States |
| Founded | 1984 |
| Industry | Scientific & Technical Instruments |
| Sector | Technology |
| Employees | 44 |
| CEO | Chun-Hsien Tsai |
Contact Details
Address: 8880 Rio San Diego Drive, Suite 800 San Diego, California 92108 United States | |
| Phone | 858 869 2986 |
| Website | ainos.com |
Stock Details
| Ticker Symbol | AIMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001014763 |
| CUSIP Number | 00902F402 |
| ISIN Number | US00902F4028 |
| Employer ID | 75-1974352 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chun-Hsien Tsai | Chief Executive Officer, President and Chairman of the Board |
| Hsin-Liang Lee | Chief Financial Officer |
| Chih-Heng Lu | Director of Corporate Developoment |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Nov 13, 2025 | 8-K | Current Report |
| Oct 17, 2025 | 8-K | Current Report |
| Oct 9, 2025 | SCHEDULE 13D/A | Filing |
| Oct 9, 2025 | SCHEDULE 13D/A | Filing |
| Oct 1, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 1, 2025 | ARS | Filing |
| Sep 8, 2025 | 8-K | Current Report |
| Sep 5, 2025 | 424B5 | Filing |
| Aug 13, 2025 | 8-K | Current Report |